Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Danaher Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $157.3B | |
|---|---|---|
| Revenue (ttm) | 25.6B | |
| Net income (ttm) | 4.3B | |
| EPS (ttm) | $6.10 | |
| Shares out | 703.5M | |
| P/E (trailing) | 38.3x | |
| P/E (forward) | 23.8x | |
| Dividend | $1.60 (0.68%) | |
| Volume | 2,725,890 | |
| Beta | 0.80 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $24.80B | $26.64B | $23.89B | $23.88B | $24.57B | -0.2% |
| Gross profit | $15.24B | $16.19B | $14.03B | $14.21B | $14.52B | -1.2% |
| Operating income | $6.38B | $7.54B | $5.20B | $4.86B | $4.69B | -7.4% |
| Net income | $6.43B | $7.21B | $4.76B | $3.90B | $3.61B | -13.4% |
| EPS (diluted) | $8.61 | $9.66 | $6.38 | $5.29 | $5.05 | -12.5% |
| EBITDA | $10.01B | $9.49B | $5.20B | $7.28B | $6.95B | -8.7% |
| R&D | $1.50B | $1.53B | $1.50B | $1.58B | $1.60B | +1.6% |
| SG&A | $6.82B | $7.12B | $7.33B | $7.76B | $8.24B | +4.8% |
Recent company headlines from major financial publishers.
Consolidated core revenue expands at 3%-4% in FY2026 and reaccelerates to 8.0% in FY2027 as customer batch manufacturing schedules normalize and deferred chromatography resin shipments deliver,. Operating margins progress from 19.09% in FY2025 to 26.5% in FY2026 and reach 28.5% over the forecast horizon,. Free cash flow conversion remains above 100%, funding debt service and regular share repurchases.
Rapid absorption of bioprocessing inventory leads to accelerated commercial batch manufacturing and new greenfield quoting. Specialty diagnostics maintain high single-digit momentum driven by DxI 9000 and Cepheid non-respiratory assays, while China hospital procurement rebounds. Operating margins expand ahead of schedule, driving strong double-digit earnings growth.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.5% | $207 | $212 | $217 | $224 | $231 |
| 8.0% | $192 | $196 | $201 | $205 | $211 |
| 8.5% | $180 | $183 | $187 | $190 | $194 |
| 9.0% | $170 | $172 | $175 | $178 | $181 |
| 9.5% | $161 | $163 | $165 | $167 | $170 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
